Woyach JA, Ruppert AS, Heerema NA, et al. Ibrutinib alone or in combination with rituximab produces superior progression free survival (PFS) compared with bendamustine plus rituximab in untreated older patients with chronic lymphocytic leukemia (CLL): results of Alliance North American Intergroup Study A041202. ASH Annual Meeting and Exposition 2018, abstract 6.
Factoren en overwegingen bij keuze af te zien van behandeling bij hematologische maligniteit
mrt 2025 | Leukemie, Lymfoom, MM